top of page
Active, not recruiting

NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in TIE NDMM

Updated: Feb 10

  • NCT04009109: Phase 2 - Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

  • TIE-NDMM

Lenalidomide Ixazomib Daratumumab

A randomized Phase II clinical trial will be conducted to assess the impact on progression free survival (PFS) with the addition of ixazomib and daratumumab to lenalidomide as a maintenance treatment following induction with lenalidomide, ixazomib, dexamethasone, and daratumumab.


Patients will be randomized to either:


Arm A: 12 cycles of lenalidomide, ixazomib, daratumumab, and dexamethasone followed by lenalidomide until disease progression or unacceptable toxicity or a maximum of 2 years of maintenance therapy.


Arm B: 12 cycles of lenalidomide, ixazomib, daratumumab and dexamethasone, followed by lenalidomide, ixazomib, and daratumumab until disease progression or unacceptable toxicity or a maximum of 2 years maintenance therapy.


Sponsor


Collaborators

Janssen Scientific Affairs, LLC

Celgene Corporation

Takeda

 

ClinicalTrials.gov Identifier: NCT04009109


Official Title: A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma


First Posted : July 5, 2019


Click here for details on ClinicalTrials.gov

 




 

Drug: Lenalidomide

Drug: Ixazomib

Drug: Daratumumab Injection

Drug: Dexamethasone

 

Locations

United States, Maine

United States, Massachusetts

United States, Michigan

United States, Nebraska

United States, North Carolina

United States, Ohio

United States, South Carolina










Posts Archive
bottom of page